← Eichor
Study identifier: NCT03977779 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis

Condition: Obstructive Jaundice · Biliary Stricture · Sphincter of Oddi Dysfunction  ·  Sponsor: Institut Paoli-Calmettes

PhaseNA
Planned participants46
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The use of an endoprothesis in a pancreatic duct is a measure to minimize the incidence and severity of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis. In this study we will evaluate the use of a Biodegradable Endoprothesis: Archimede Fast Biodegradable Pancreatic Stent in patients with high risk of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis.The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography. The efficacy and the security of the device will be evaluated.

This description comes directly from the study's public registry record.

Talk to the study team

Dominique Genre, MD  ·  +33491223778  ·  drci.up@ipc.unicancer.fr

Marc Giovannini, MD  ·  giovanninim@ipc.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Institut Paoli CalmettesMarseille, Provence-Alpes-Côte d'Azur Region, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03977779